Cardiovascular Systems is a medical devices business based in the US. Cardiovascular Systems shares (CSII) are listed on the NASDAQ and all prices are listed in US Dollars. Cardiovascular Systems employs 725 staff and has a trailing 12-month revenue of around $239.8 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $20.00 |
|---|---|
| 52-week range | $0.00 - $0.00 |
| 50-day moving average | $19.84 |
| 200-day moving average | $15.84 |
| Wall St. target price | $17.33 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.96 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $20 from 2023-05-02
| 1 week (2024-09-19) | N/A |
|---|---|
| 1 month (2024-08-26) | N/A |
| 3 months (2024-06-26) | N/A |
| 6 months (2024-03-26) | N/A |
| 1 year (2023-09-26) | N/A |
|---|---|
| 2 years (2022-09-30) | 44.30% |
| 3 years (2021-09-30) | 32.83 |
| 5 years (2019-09-30) | 47.52 |
Valuing Cardiovascular Systems stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cardiovascular Systems's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cardiovascular Systems's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 177.27. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Cardiovascular Systems's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $239.8 million |
|---|---|
| Gross profit TTM | $172.8 million |
| Return on assets TTM | -7.56% |
| Return on equity TTM | -15.18% |
| Profit margin | -15.79% |
| Book value | $5.70 |
| Market Capitalization | $844 million |
TTM: trailing 12 months
We're not expecting Cardiovascular Systems to pay a dividend over the next 12 months.
Cardiovascular Systems's shares were split on a 1:10 basis on 25 February 2009. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cardiovascular Systems shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Cardiovascular Systems shares which in turn could have impacted Cardiovascular Systems's share price.
Over the last 12 months, Cardiovascular Systems's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cardiovascular Systems's is 0.737. This would suggest that Cardiovascular Systems's shares are less volatile than average (for this exchange).
Cardiovascular Systems, Inc. , a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. In addition, it offers guidewires, catheters, balloons, embolic protection system, and other OAS support products. Cardiovascular Systems, Inc. has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons.
Step 1: Open and fund your account, Step 2: Enable options trading, Step 3: Select and trade options, Step 4: Closing options trades.
Learn the basics of put options: what they are, how they work and a few examples.
Learn the basics of call options: what they are, how they work and examples.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
Check out the best-performing ETFs so far in 2024.
What to expect when you sign up for a Zacks Trade brokerage account.